Oral ziprasidone in the treatment of schizophrenia: A review of short-term trialsKANE, John M.The Journal of clinical psychiatry. Supplement. 2003, Vol 64, Num 19, pp 19-25, 7 p.Article

Lurasidone: A Clinical OverviewKANE, John M.The Journal of clinical psychiatry. Supplement. 2011, Vol 72, Num 1, pp 24-28, 5 p.Article

Strategies for Making an Accurate Differential Diagnosis of Schizoaffective DisorderKANE, John M.The Journal of clinical psychiatry. Supplement. 2010, Vol 71, Num 2, pp 4-7, 4 p.Article

Treatment Strategies to Prevent Relapse and Encourage RemissionKANE, John M.The Journal of clinical psychiatry. Supplement. 2007, Vol 68, Num 14, pp 27-30, 4 p.Article

Teaching and practicing psychopharmacologyKANE, John M.The Journal of clinical psychiatry. 2007, Vol 68, Num 11, pp 1807-1808, issn 0160-6689, 2 p.Article

Tardive dyskinesia rates with atypical antipsychotics in adults: Prevalence and incidenceKANE, John M.The Journal of clinical psychiatry. Supplement. 2004, Vol 65, Num 9, pp 16-20, 5 p.Conference Paper

Ziprasidone in schizophrenia: from acute treatment to long-term managementKANE, John M.The Journal of clinical psychiatry. Supplement. 2003, Vol 64, Num 19, 49 p.Serial Issue

Recent Advances in Treatments for SchizophreniaKANE, John M.The Journal of clinical psychiatry. Supplement. 2011, Vol 72, Num 1, 27 p.Serial Issue

Intramuscular ziprasidone: Moving beyond the conventional in the treatment of acute agitation in schizophreniaBROOK, Shlomo.The Journal of clinical psychiatry. Supplement. 2003, Vol 64, Num 19, pp 13-18, 6 p.Article

How can we improve compliance in schizophrenia? Satellite SymposiumKANE, John M; FARDE, Lars.International clinical psychopharmacology. 1997, Vol 12, issn 0268-1315, 49 p., SUP1Conference Proceedings

Sudden Deaths in Psychiatric PatientsMANU, Peter; KANE, John M; CORRELL, Christoph U et al.The Journal of clinical psychiatry. 2011, Vol 72, Num 7, pp 936-941, issn 0160-6689, 6 p.Article

Clinical experience with risperidoneMARDER, S. R.The Journal of clinical psychiatry. 1996, Vol 57, pp 57-61, issn 0160-6689, SUP9Conference Paper

Atypical Antipsychotics : Sedation Versus EfficacyKANE, John M; SHARIF, Zafar A.The Journal of clinical psychiatry. Supplement. 2008, Vol 69, Num 1, pp 18-31, 14 p.Article

What can we achieve by implementing a compliance-improvement program?KANE, J. M.International clinical psychopharmacology. 1997, Vol 12, pp S43-S46, issn 0268-1315, SUP1Conference Paper

Maintenance therapy of persons with schizophreniaCARPENTER, W. T.The Journal of clinical psychiatry. 1996, Vol 57, pp 10-18, issn 0160-6689, SUP9Conference Paper

Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndromePETERSON, B. S.The Journal of clinical psychiatry. 1996, Vol 57, pp 24-34, issn 0160-6689, SUP9Conference Paper

Adjunctive armodafinil for negative symptoms in adults with schizophrenia: A double-blind, placebo-controlled studyKANE, John M; RONGHUA YANG; YOUAKIM, James M et al.Schizophrenia research. 2012, Vol 135, Num 1-3, pp 116-122, issn 0920-9964, 7 p.Article

Asenapine: A Clinical OverviewPOTKIN, Steven G.The Journal of clinical psychiatry. Supplement. 2011, Vol 72, Num 1, pp 14-18, 5 p.Article

Past and Present Progress in the Pharmacologic Treatment of SchizophreniaKANE, John M; CORRELL, Christoph U.The Journal of clinical psychiatry. 2010, Vol 71, Num 9, pp 1115-1124, issn 0160-6689, 10 p.Article

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year StudiesCORRELL, Christoph U; LEUCHT, Stefan; KANE, John M et al.The American journal of psychiatry. 2004, Vol 161, Num 3, pp 414-425, issn 0002-953X, 12 p.Article

Tolerability of ziprasidone: An expanding perspectiveDANIEL, David G.The Journal of clinical psychiatry. Supplement. 2003, Vol 64, Num 19, pp 40-49, 10 p.Article

Creating a Health Care Team to Manage Chronic Medical Illnesses in Patients With Severe Mental Illness: The Public Policy PerspectiveKANE, John M.The Journal of clinical psychiatry. Supplement. 2009, Vol 70, Num 3, pp 37-42, 6 p.Article

Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: Clinical studiesKANE, John M.The Journal of clinical psychiatry. Supplement. 2003, Vol 64, Num 16, pp 34-40, 7 p.Article

Towards the improvement of compliance : the significance of psycho-education and new antipsychotic drugsGAEBEL, W.International clinical psychopharmacology. 1997, Vol 12, pp S37-S42, issn 0268-1315, SUP1Conference Paper

Pharmacoeconomics of antipsychotic drug therapyHARGREAVES, W. A; SHUMWAY, M.The Journal of clinical psychiatry. 1996, Vol 57, pp 66-76, issn 0160-6689, SUP9Conference Paper